Ariel Yusupov has over a decade of experience in academia and industry, with expertise in prostate cancer, nucleic acid-based therapeutics, immunotherapy, and gene therapy. His industry experiences at Pfizer and Johnson and Johnson involved him leading development of nucleic acid-based therapeutics, AAV-based gene therapy, and CAR-T cell therapy from discovery to Phase III. At Pfizer, he was a foundational scientist on the mRNA vaccine discovery team. He then joined the Cell, Gene Therapy and Vaccines team at Johnson and Johnson to lead development of a self-amplifying RNA-based therapy for chronic hepatitis B, in addition to leading development efforts for the AAV-based gene therapy and the BCMA CAR-T programs. This experience, in combination of his over decade of prostate cancer research, has led him to pursue his own invention as the founder of FIG Therapeutics.